content_image/218773.jpg
<img src='content_image/218773.jpg'>

## Kristalose ® 

As the only prescription laxative available in a powder formulation, Kristalose ®  (lactulose) for Oral Solution provides patients with distinct benefits. 

A unique, dry powder crystalline formulation of lactulose used to treat chronic and acute constipation, Kristalose is the only prescription laxative available in pre-measured powder packets, making it easily portable. Kristalose dissolves quickly in four ounces of water, offering patients a virtually taste-free, grit-free and essentially calorie- free alternative to lactulose syrups. A preference trial shows 77 percent of patients surveyed prefer the taste, consistency and portability of Kristalose over similar products in syrup forms. 

Since acquiring exclusive U.S. commercial rights to Kristalose in 2006, Cumberland has marketed the product to gastroenterologists, internists and other high prescribers of laxatives. Using the preference data as a cornerstone of our marketing efforts, we have made significant gains following our repositioning of the brand in early 2014. The new marketing strategy includes an enhanced coupon program for the product, which allows us to provide additional support to patients. As a result of these efforts, Kristalose now ranks as the Company’s top selling product. 

“Our gastroenterology products have been a significant driver of growth for the Company. With the addition of Omeclamox-Pak and the repositioning of Kristalose, we are creating increased demand while while maximizing the use of our internal resources. We see a bright future for both brands.” 

## Omeclamox ® -Pak 

Omeclamox ® -Pak is a branded prescription product that combines three well-known and widely prescribed medications for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Packaged together for patient convenience, Omeclamox-Pak combines omeprazole, amoxicillin and clarithromycin in a simple-to-follow 10-day course of therapy that has been shown to eradicate H. pylori in up to 90 percent of patients. 

It is the first FDA-approved triple therapy combination medication to contain omeprazole as the proton pump inhibitor, which works to decrease the amount of acid the stomach produces. Amoxicillin and clarithromycin are both antibiotic agents, which allow the stomach to heal by hindering the growth of H. pylori. 

After acquiring rights to the brand through an agreement with Pernix Therapeutics in October 2013, Cumberland’s field sales force began promoting the product to the gastroenterology market alongside Kristalose in January 2014. Under the terms of the agreement, Cumberland is responsible for the product’s U.S. marketing and distribution, as well as promotion to gastroenterologists, while Pernix promotes the product to select primary care and other physicians. 

In the year since its launch, Omeclamox-Pak has proven to be an excellent strategic fit as evidenced by a significant increase in prescriptions among our target physicians. 

